No Data
Press Release: CRISPR Therapeutics Proposes New Appointment to the Board of Directors
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $85
Cathie Wood's ARK Innovation ETF Couldn't Keep Up in 2024
CRISPR Therapeutics AG's (NASDAQ:CRSP) Recent 4.5% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?
Institutional Investors May Adopt Severe Steps After CRISPR Therapeutics AG's (NASDAQ:CRSP) Latest 8.3% Drop Adds to a Year Losses